A New Front in Opioid Care: MedMark Integrates Flexible Buprenorphine Treatment

LEWISVILLE, TX – September 01, 2026 – MedMark Treatment Centers, a major provider of opioid addiction services, today announced a significant strategic expansion that reflects a critical evolution in the nation's battle against the opioid crisis. The company is integrating office-based opioid treatment (OBOT) with buprenorphine into 25 of its existing centers across nine states, which have historically focused on methadone maintenance programs.

This move by MedMark, part of North America's largest medication-assisted treatment (MAT) provider BayMark Health Services, is more than a simple service line extension. It signals a deeper alignment with a national push for more flexible, patient-centered care models at a time when the opioid epidemic, now dominated by synthetic opioids like fentanyl, continues to claim tens of thousands of lives annually. While national overdose deaths saw a welcome decrease in the last year, states like Florida, Illinois, and Alabama—all part of this expansion—are still grappling with the devastating fallout. By co-locating buprenorphine services with established methadone programs, MedMark is creating a more comprehensive and adaptable infrastructure to meet patients where they are.

A More Flexible Frontline: The Shift to Integrated Care

The core of MedMark's initiative lies in offering a choice between two of the most effective, evidence-based medications for opioid use disorder (OUD). For decades, methadone has been a cornerstone of treatment, highly effective but also highly regulated. It requires patients, especially early in their treatment, to visit a certified Opioid Treatment Program (OTP) daily for their dose, a structure that provides stability but can also be a significant barrier due to work, family, or travel constraints.

Buprenorphine, often prescribed in a combination formula like Suboxone®, represents a more decentralized and flexible model. Administered through an OBOT setting, which functions more like a traditional doctor's office, eligible patients can receive a prescription for up to a month at a time. This dramatically reduces the burden of daily clinic visits and the stigma some associate with them.

“Treatment for opioid use disorder is not one-size-fits-all,” said Dan Greer, Senior Vice President of Opioid Treatment Programs at BayMark Health Services. “Expanding buprenorphine services at MedMark locations that already provide methadone treatment allows us to offer patients more options while keeping their care connected through an experienced treatment team.”

This integrated approach directly addresses a well-documented patient preference for autonomy. Research consistently shows that patients value the convenience and discretion of buprenorphine treatment. “The ability to pick up a script and not structure my entire week around clinic visits has been life-changing,” one patient in a similar program noted anonymously. This flexibility can lead to better treatment retention, which is a key predictor of long-term recovery. Studies have shown that patients remaining in OBOT for a year or more have a significantly lower risk of relapse.

The Regulatory Tailwinds and Lingering Headwinds

MedMark's expansion is buoyed by significant regulatory shifts designed to broaden access to OUD treatment. The most impactful of these was the 2022 elimination of the federal “X-waiver,” a long-standing requirement that mandated special certification for clinicians to prescribe buprenorphine. In theory, its removal allows any provider with a standard DEA license to prescribe the medication, dramatically expanding the potential pool of prescribers.

However, the real-world impact has been mixed. While some data shows a modest increase in buprenorphine initiation, other analyses suggest the waiver's removal alone has not been a panacea. Systemic barriers, including lack of institutional support, inadequate training, and persistent stigma within the medical community, continue to limit the number of clinicians willing to treat OUD. As one addiction specialist commented, “Prescribing is the easy part; the real work is building the support systems to address the housing, mental health, and transportation barriers that prevent consistent treatment.”

Furthermore, insurance coverage remains a complex hurdle. While most Medicaid and commercial plans cover buprenorphine, administrative obstacles like prior authorizations and dosage limits can delay or disrupt care. This expansion into states with varying funding mechanisms—from settlement-funded trusts in Georgia and Indiana to state-managed grants in Florida and Arkansas—will test the ability of providers to navigate these fragmented payment landscapes to ensure consistent patient access.

Local Impact and the National Picture

The 25-center expansion spans a wide geographic and demographic cross-section of America, including locations in Alabama, Arkansas, Florida, Georgia, Illinois, Indiana, New Mexico, North Carolina, and Texas. In states like Illinois, which saw a remarkable 35.6% drop in opioid overdose deaths last year, increased access to flexible treatment could help sustain that positive trend. In Texas, where methamphetamine has recently overtaken fentanyl in overdose deaths, a robust and adaptable OUD treatment infrastructure remains vital to prevent a resurgence.

By bringing these services into established community centers, MedMark aims to leverage local trust and familiarity. “Bringing these services together strengthens our ability to meet patients where they are in their recovery journey,” said Evelyn Sosa, another Senior Vice President at BayMark. “Whether methadone or buprenorphine is determined to be the appropriate option, patients can receive treatment from a trusted local team focused on helping them build stability and move forward.”

This integrated model positions MedMark to effectively compete with other major providers like Acadia Healthcare, which is also aggressively expanding its OUD treatment footprint. The key differentiator for MedMark is not just adding buprenorphine, but weaving it into the fabric of existing methadone clinics. This creates a seamless continuum where a patient whose circumstances change—for instance, needing the higher structure of methadone initially before transitioning to the flexibility of buprenorphine—can do so without having to find a new provider and start over. This continuity of care is precisely what experts argue is essential for navigating the chronic nature of addiction and fostering sustained recovery.